NCT06254495 is a Phase 1 clinical trial of PF-08046044/SGN-35C in Hodgkin Disease, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Who is sponsoring NCT06254495?

NCT06254495 is sponsored by Seagen, a wholly owned subsidiary of Pfizer.

What drugs are being tested in NCT06254495?

Interventions in NCT06254495: PF-08046044/SGN-35C.

What condition does NCT06254495 study?

NCT06254495 studies Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic.

Is NCT06254495 still recruiting?

NCT06254495 is currently active, enrolled. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT06254495

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Active, enrolled Phase 1 Last updated 7 April 2026

What this trial tests

Phase 1 trial testing PF-08046044/SGN-35C in Hodgkin Disease in 57 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

28 May 2024

Primary endpoint
18 April 2028

18 April 2029

Quick facts

Lead sponsor	Seagen, a wholly owned subsidiary of Pfizer
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	28 May 2024
Primary completion	18 April 2028
Estimated completion	18 April 2029
Sites	32 locations across Denmark, France, Italy, United Kingdom, United States, Spain

Drugs / interventions tested

PF-08046044/SGN-35C (pf-08046044-sgn-35c) — full drug profile →

Conditions studied

Hodgkin Disease — all drugs for Hodgkin Disease →
Lymphoma, T-Cell, Peripheral — all drugs for Lymphoma, T-Cell, Peripheral →
Lymphoma, Large B-Cell, Diffuse — all drugs for Lymphoma, Large B-Cell, Diffuse →
Lymphoma, Large-Cell, Anaplastic — all drugs for Lymphoma, Large-Cell, Anaplastic →

Sponsor

Seagen, a wholly owned subsidiary of Pfizer — full company profile →

Who can join

18 and older, any sex, with Hodgkin Disease or Lymphoma, T-Cell, Peripheral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.
Chow R, Zhang D, Kannout S, Ma A, et al · · 2026 · PMID 42068413 · DOI 10.1007/s00520-026-10674-2
EHA2024 Hybrid Congress
· 2024

Verify or expand the search:

Other recruiting trials for Hodgkin Disease

Currently open trials in the same condition.

NCT04671693 — A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Sur · NA · active not recruiting
NCT02979522 — A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage · Phase 1, PHASE2 · active not recruiting
NCT02682667 — Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · recruiting
NCT01676805 — Tissue Collection for Studies of Lymph Cancer · recruiting
NCT00039676 — Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer · active not recruiting

Other Seagen, a wholly owned subsidiary of Pfizer trials

Trials by the same sponsor.

NCT06549816 — A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors · Phase 1 · completed
NCT06466187 — A Study of SGN-MesoC2 in Advanced Solid Tumors · Phase 1 · active not recruiting
NCT06157892 — A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors · Phase 2 · recruiting
NCT06120504 — A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers · Phase 1 · terminated
NCT06012435 — A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06254495 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seagen, a wholly owned subsidiary of Pfizer
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06254495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing